HUP0101804A3 - Adjuvant composition and methods for its use - Google Patents

Adjuvant composition and methods for its use

Info

Publication number
HUP0101804A3
HUP0101804A3 HU0101804A HUP0101804A HUP0101804A3 HU P0101804 A3 HUP0101804 A3 HU P0101804A3 HU 0101804 A HU0101804 A HU 0101804A HU P0101804 A HUP0101804 A HU P0101804A HU P0101804 A3 HUP0101804 A3 HU P0101804A3
Authority
HU
Hungary
Prior art keywords
methods
adjuvant composition
adjuvant
composition
Prior art date
Application number
HU0101804A
Other languages
English (en)
Original Assignee
Corixa Corp Seattle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp Seattle filed Critical Corixa Corp Seattle
Publication of HUP0101804A2 publication Critical patent/HUP0101804A2/hu
Publication of HUP0101804A3 publication Critical patent/HUP0101804A3/hu
Publication of HU225844B1 publication Critical patent/HU225844B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Biological Depolymerization Polymers (AREA)
HU0101804A 1998-05-07 1999-05-07 Adjuvant composition and its use HU225844B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8467898P 1998-05-07 1998-05-07
PCT/US1999/009978 WO1999056776A2 (en) 1998-05-07 1999-05-07 Adjuvant composition and methods for its use

Publications (3)

Publication Number Publication Date
HUP0101804A2 HUP0101804A2 (hu) 2001-11-28
HUP0101804A3 true HUP0101804A3 (en) 2003-11-28
HU225844B1 HU225844B1 (en) 2007-10-29

Family

ID=22186530

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101804A HU225844B1 (en) 1998-05-07 1999-05-07 Adjuvant composition and its use

Country Status (20)

Country Link
US (2) US6630161B1 (hu)
EP (1) EP1075276B1 (hu)
JP (1) JP2002513773A (hu)
KR (1) KR100682154B1 (hu)
CN (2) CN101219217A (hu)
AT (1) ATE375803T1 (hu)
AU (1) AU755445B2 (hu)
BR (1) BR9910269A (hu)
CA (1) CA2330610A1 (hu)
CY (1) CY1107265T1 (hu)
DE (1) DE69937343T2 (hu)
DK (1) DK1075276T3 (hu)
ES (1) ES2296390T3 (hu)
HK (1) HK1039072A1 (hu)
HU (1) HU225844B1 (hu)
NO (1) NO20005596L (hu)
NZ (1) NZ508013A (hu)
PT (1) PT1075276E (hu)
WO (1) WO1999056776A2 (hu)
ZA (1) ZA200006379B (hu)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6630161B1 (en) * 1998-05-07 2003-10-07 Ribi Immunochem Research, Inc. Adjuvant composition and methods for its use
DE19859045A1 (de) 1998-12-21 2000-06-29 Fresenius Pharma Austria Gmbh Emulsion vom Typ Öl in Wasser mit Schutzwirkung gegen Peroxidationsschäden an menschlichen Organen, deren Herstellung und Verwendung
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US20030031684A1 (en) * 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US7470791B2 (en) 2003-03-10 2008-12-30 Nycomed Gmbh Process for the preparation of roflumilast
SI1651265T1 (sl) 2003-07-24 2008-10-31 Merial Ltd Formulacije cepiva, ki obsegajo emulzijo olje v vodi
ZA200700457B (en) 2004-06-15 2008-08-27 New York Blood Ct Inc Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
DE102004046235A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
CN1320924C (zh) * 2005-01-07 2007-06-13 邢为藩 一种自乳化疫苗佐剂及其制备方法
ES2421916T3 (es) 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
AU2006226458B2 (en) 2005-03-23 2012-08-30 Glaxosmithkline Biologicals S.A. Novel composition
WO2006116423A2 (en) 2005-04-26 2006-11-02 Eisai Co., Ltd Compositions and methods for cancer immunotherapy
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
WO2007052155A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US7848801B2 (en) 2005-12-30 2010-12-07 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
KR20110110853A (ko) 2006-01-27 2011-10-07 노파르티스 파르마 아게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
EP2007765B1 (en) * 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
US20100010217A1 (en) * 2006-03-23 2010-01-14 Valiante Nicholas M Methods for the preparation of imidazole-containing compounds
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
KR101696727B1 (ko) 2006-07-17 2017-01-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 인플루엔자 백신
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP3456348A1 (en) 2006-09-11 2019-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CA2671629C (en) 2006-12-06 2017-08-15 Novartis Ag Vaccines including antigen from four strains of influenza virus
EP2123259A1 (en) * 2007-01-16 2009-11-25 Hokkaido University Liposome preparation for iontophoresis having antioxidant component encapsulated therein
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
HUE025149T2 (hu) 2007-08-02 2016-01-28 Biondvax Pharmaceuticals Ltd Multimer multiepitóp influenza vakcinák
WO2009039628A1 (en) 2007-09-27 2009-04-02 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
US20110236470A1 (en) 2008-12-03 2011-09-29 Yaffa Mizrachi Nebenzahl GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
CA2752039A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原
CN109248313B (zh) 2009-04-14 2023-01-17 葛兰素史密丝克莱恩生物有限公司 用于免疫接种以抵御金黄色葡萄球菌的组合物
RU2732574C2 (ru) 2009-06-05 2020-09-21 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
ES2662716T3 (es) 2009-07-07 2018-04-09 Glaxosmithkline Biologicals Sa Inmunógenos conservados de Escherichia coli
MX2012000734A (es) 2009-07-16 2012-01-27 Novartis Ag Inmunogenos destoxificados de escherichia coli.
RU2555342C2 (ru) 2009-09-10 2015-07-10 Мериал Лимитед Новые вакцинные составы, включающие сапонинсодержащие адъюванты
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
AR074485A1 (es) * 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
WO2011112871A1 (en) 2010-03-11 2011-09-15 Immune Design Corp. Vaccines for pandemic influenza
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
JP6191082B2 (ja) 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム より低用量の抗原および／またはアジュバントを有する混合ワクチン
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2012149307A2 (en) 2011-04-27 2012-11-01 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
JP6240077B2 (ja) 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
WO2013057715A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
US20150044251A1 (en) 2011-12-23 2015-02-12 Novartis Ag Stable compositions for immunising against staphylococcus aureus
CN110339160A (zh) 2012-02-07 2019-10-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
EP3492095A1 (en) 2012-04-01 2019-06-05 Technion Research & Development Foundation Limited Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
GB201212010D0 (en) * 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
HUE044211T2 (hu) 2012-08-31 2019-10-28 Glaxosmithkline Biologicals Sa Staphylococcus aureus elleni immunizálásra szolgáló, stabilizált fehérjék
US20150203543A1 (en) 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
AU2013311702A1 (en) 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
EP2903650B1 (en) 2012-10-02 2018-04-04 GlaxoSmithKline Biologicals SA Nonlinear saccharide conjugates
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
SG11201502599TA (en) 2012-10-12 2015-05-28 Glaxosmithkline Biolog Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
PL2925355T3 (pl) 2012-11-30 2018-06-29 Glaxosmithkline Biologicals S.A. Antygeny pseudomonas i połączenia antygenów
BR112015014250A2 (pt) 2012-12-18 2017-07-11 Glaxosmithkline Biologicals Sa método para imunizar um bebê, vacina de combinação e, kit
CA2903345A1 (en) * 2013-03-19 2014-09-25 Biotech Tools S.A. Allergen preparation
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CA2944768C (en) 2014-04-03 2022-08-30 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
CN107405395A (zh) * 2015-03-17 2017-11-28 红杉科学有限公司 疫苗与佐剂的组合物以及治疗尿路感染的方法
EP3069729A1 (en) 2015-03-17 2016-09-21 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
JP6830070B2 (ja) 2015-07-07 2021-02-17 セキラス ユーケー リミテッドＳｅｑｉｒｕｓ ＵＫ Ｌｉｍｉｔｅｄ インフルエンザ効力アッセイ
KR101996538B1 (ko) * 2017-02-13 2019-07-04 단디바이오사이언스 주식회사 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도
CN107397956A (zh) * 2017-08-08 2017-11-28 南开大学 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用
US20210340185A1 (en) 2018-08-29 2021-11-04 Centre Hospitalier Universitaire Vaudois Ebola vaccine compositions and methods of using same
SG11202105787QA (en) * 2018-12-26 2021-06-29 Sumitomo Dainippon Pharma Co Ltd Preparation including vaccine adjuvant
JP2023502650A (ja) 2019-11-18 2023-01-25 セキラス ピーティーワイ リミテッド 遺伝子再集合インフルエンザウイルスを産生するための方法
CN115300490B (zh) * 2021-05-07 2024-04-16 安徽远望乐桓药业有限公司 包含角鲨烯和甘露醇的药物组合物及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
ES502788A0 (es) * 1981-06-04 1982-04-01 Landerlan Sa Lab Procedimiento de preparacion de imuno globulina g nativa li-bre de actividad anticomplementaria
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4857318A (en) * 1983-11-07 1989-08-15 Syntex (U.S.A.) Inc. Bordetella bronchiseptica pilus subunit protein vaccine effective against bordetella pertussis
US5948769A (en) * 1984-01-28 1999-09-07 Ismail; Roshdy Agent for treating heart diseases
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
JPS63152327A (ja) * 1987-11-20 1988-06-24 Toyama Chem Co Ltd 脂肪乳剤から成る溶血防止用組成物を含有する製剤
EP0324455A3 (en) * 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
HU198843B (en) * 1988-02-08 1989-12-28 Frigyes Kovacs Process for producing veterinary compositions with disinfecting and antiinflammatory action, comprising natural active ingredient and suitable particularly for treating mastitis
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH02152931A (ja) * 1988-12-02 1990-06-12 Green Cross Corp:The Ｂ型肝炎ワクチン
US5171737A (en) * 1989-03-03 1992-12-15 The Liposome Company, Inc. Emulsions
US5858769A (en) * 1989-05-15 1999-01-12 Akzo Nobel N.V. Device for detecting microorganisms
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
DE4019062A1 (de) * 1989-08-30 1991-03-07 Kali Chemie Ag Stabilisierung von perfluorcarbonemulsionen und als emulsionsstabilisierende zusaetze verwendbare perfluorierte heterocyclische verbindungen
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
US5324512A (en) * 1990-12-26 1994-06-28 The Population Council [Gln']-luteinizing hormone releasing hormone conjugate of tetanus vaccine and its uses
US5387421A (en) * 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
PT705109E (pt) * 1993-05-25 2001-02-28 American Cyanamid Co Adjuvantes para vacinas contra virus sinciciais respiratorios
US5773011A (en) * 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2715843B1 (fr) * 1994-02-09 1996-04-12 Oreal Compositions cosmétiques antisolaires, procédé de préparation et utilisation.
FR2716372B1 (fr) * 1994-02-18 1996-04-12 Oreal Compositions cosmétiques antisolaires stables, fluides et/ou fluidifiables, procédé de préparation et utilisation.
AU1566095A (en) * 1994-02-24 1995-09-11 Micro-Pak, Inc. Vaccines containing paucilamellar lipid vesicles as immunological adjuvants
FR2716622B1 (fr) * 1994-02-28 1996-04-12 Oreal Compositions cosmétiques autobronzantes à base de dihydroxyacétone, procédé de préparation et utilisation.
AU3533395A (en) * 1994-09-30 1996-04-26 Takeda Chemical Industries Ltd. Oral sustained-release preparation
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
EP0852941B1 (de) * 1996-12-13 2003-05-14 Vesifact Ag Kosmetische Präparate in Form einer Nanodispersion
WO1998053799A2 (en) * 1997-05-28 1998-12-03 Jenner Biotherapies, Inc. Immunogenic compositions
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
US6630161B1 (en) * 1998-05-07 2003-10-07 Ribi Immunochem Research, Inc. Adjuvant composition and methods for its use
DE69920380T2 (de) * 1998-12-18 2005-11-17 Shin-Etsu Chemical Co., Ltd. Organopolysiloxan Öl-in-Wasser Emulsion und Verfahren zur Herstellung
US6288026B1 (en) * 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US6551598B2 (en) * 2000-01-21 2003-04-22 Merial Vaccination against canine herpesvirosis and vaccines therefor

Also Published As

Publication number Publication date
KR100682154B1 (ko) 2007-02-12
NZ508013A (en) 2003-08-29
BR9910269A (pt) 2001-01-09
HU225844B1 (en) 2007-10-29
CN1306438A (zh) 2001-08-01
CA2330610A1 (en) 1999-11-11
DK1075276T3 (da) 2008-02-11
NO20005596D0 (no) 2000-11-06
EP1075276B1 (en) 2007-10-17
HUP0101804A2 (hu) 2001-11-28
DE69937343T2 (de) 2008-07-24
DE69937343D1 (de) 2007-11-29
KR20010043404A (ko) 2001-05-25
JP2002513773A (ja) 2002-05-14
WO1999056776A3 (en) 2000-01-06
ZA200006379B (en) 2002-01-07
AU3973799A (en) 1999-11-23
PT1075276E (pt) 2008-01-22
HK1039072A1 (zh) 2002-04-12
CN101219217A (zh) 2008-07-16
AU755445B2 (en) 2002-12-12
NO20005596L (no) 2001-01-05
CY1107265T1 (el) 2012-11-21
US6630161B1 (en) 2003-10-07
ATE375803T1 (de) 2007-11-15
ES2296390T3 (es) 2008-04-16
US20030215497A1 (en) 2003-11-20
WO1999056776A2 (en) 1999-11-11
EP1075276A2 (en) 2001-02-14

Similar Documents

Publication Publication Date Title
HUP0101804A3 (en) Adjuvant composition and methods for its use
SG79294A1 (en) Polishing composition and polishing method employing it
SG88775A1 (en) Polishing composition and polishing method employing it
PL343065A1 (en) Vaccine composition
HU9900592D0 (en) Compound and its use
EP1102535A4 (en) COMPOUNDS AND METHODS
GB2341190B (en) Polishing composition
GB9813271D0 (en) Composition and use
PL350163A1 (en) Adjuvant composition
PL347357A1 (en) Novel composition and use
GB2338490B (en) Polishing composition
EP1056456A4 (en) R-LANSOPRAZOL COMPOSITIONS AND TREATMENTS THEREFOR
SG94358A1 (en) Polishing composition and method
EP1056457A4 (en) S-LANSOPRAZOLE COMPOSITIONS AND METHODS OF USE
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
EP1056455A4 (en) EPIMORPHIN COMPOUND AND USE OF THE SAME
GB9806788D0 (en) Composition
EP1073333A4 (en) S-RABEPRAZOL COMPOSITIONS AND METHODS
GB9803232D0 (en) Compound composition and use
GB9803506D0 (en) Composition and method
GB9801870D0 (en) Vaccine composition
GB9804041D0 (en) Composition
EP1073332A4 (en) R-RABEPRAZOL COMPOSITIONS AND METHODS
HUP0100613A3 (en) Methods and compositions for stabilizing acetylcholine compositions
GB9805172D0 (en) Composition and use

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees